Most people who find their way to psychedelic therapy have already done everything right. They’ve tried multiple medications, therapy, combinations of both— And they still struggle to feel like themselves.
If that’s where you are, you’re not failing. You may just be dealing with something that standard treatment wasn’t built to fully address. We’re here to tell you, hope is on the horizon with new therapies being approved.
Most people who find their way to psychedelic therapy have already done everything right. They’ve tried multiple medications, therapy, combinations of both— And they still struggle to feel like themselves.
If that’s where you are, you’re not failing. You may just be dealing with something that standard treatment wasn’t built to fully address. We’re here to tell you, hope is on the horizon with new therapies being approved.
A promising new category of treatment is moving through clinical trials right now, developed specifically for people who haven’t had success with the current standards in treatment. In this article we’ll tell you what’s coming, how it works, and what’s already available to you in New Jersey today.
A Treatment With a Long History and a Promising Future
Psychedelics weren’t always associated with counterculture. For a brief window in the 1950s and early ‘60s, they were medicine.
More than 1,000 scientific papers were published, and around 40,000 patients participated in studies exploring LSD and psilocybin for mental health condition and early results showed genuine promise. Researchers used these compounds as aids to psychotherapy for depression and alcohol dependence. Sources: Healthyfamily4life, PubMed Central
Then came the ‘70s. President Nixon introduced the Controlled Substances Act, rendering psilocybin, mescaline, LSD, and DMT illegal. Government-sanctioned psychedelic research came to a halt for the next three decades. Source: The Beckley Foundation
The research came back slowly in the ‘90s and ‘00s, driven in part by growing evidence of MDMA’s therapeutic benefits. By the 2010s, major universities and research institutions were running clinical trials again. Today, psychedelic therapy is in the final stages of the FDA approval process. Source: EBSCO
The science and research that was paused for 30 years is finally catching up.
Why This Matters: The Gaps in Current Treatment
About a third of people diagnosed with major depressive disorder experience treatment-resistant depression. That’s not a failure of effort—that’s people who’ve done everything right: therapy, medication, or a combination of both. And still haven’t found lasting relief.
Additionally, an estimated 40-60% of people diagnosed with PTSD don’t respond to first-line medications. Source: APA
That’s millions of people living with conditions that current treatments weren’t built to fully address. Researchers are actively developing new psychedelic-assisted therapies specifically for people in that gap.
If that sounds like your experience, you’re not out of options. And you’re not out of time.
What’s Actually Being Studied Right Now
Two compounds are at the forefront of this research.
Psilocybin (the active compound in “magic mushrooms”) is the furthest along in the FDA approval process for depression. MDMA (sometimes called ecstasy) has been extensively studied for PTSD, though its FDA path has hit a significant obstacle.
Here’s where each one stands:
Psilocybin for Depression
Compass Pathways has run the largest randomized, controlled psilocybin trials ever conducted. Their first Phase 3 trial showed a statistically significant reduction in depression symptom severity compared to placebo, with no unexpected safety issues.
Following equally positive results from a second Phase 3 trial, Compass plans to submit a rolling FDA application between October and December 2026. If approved, their treatment would become the first classic psychedelic medication cleared for the U.S. market. Source: Psychiatry Times
MDMA for PTSD
MDMA-assisted therapy has produced some of the most compelling PTSD results in psychiatric research. In clinical trials, 67% of patients who received MDMA-assisted therapy no longer met PTSD criteria after treatment, compared to just 32% in the placebo group. Source: Live Science
The FDA declined to approve MDMA in 2024, asking for additional research before moving forward. The science isn’t in question. The approval pathway needed refinement. Research continues, and the results remain among the strongest in the field. Source: Statnews
The Bigger Picture
In April 2026, the FDA announced it is fast-tracking the review and approval process for three companies studying psilocybin and an MDMA-like compound as treatments for depression and PTSD. The regulatory environment is the most favorable it’s ever been for psychedelic medicine. Source: Scientific American
What Does Psychedelic Therapy Actually Feel Like?
The way psychedelic therapy feels is usually the first thing people want to know, and it’s a completely reasonable thing to wonder about.
Psilocybin therapy isn’t like taking a pill and going home. It happens in a clinical setting, with trained therapists present throughout the entire experience.
Effects typically begin within 30 to 90 minutes. Patients often experience meaningful changes in perception, mood, and thinking during this time. Many describe a sense of deep introspection, old thought patterns seen from a new perspective, feelings of emotional release and a sense of connection they hadn’t felt in years.
At Oasis, that preparation starts at your very first conversation, before any treatment begins. Our care team will help prepare you with what to expect, what comes next and help you develop trust in the process.
After the experience, many patients report relief from depression symptoms lasting weeks or even months. Patients in trials have described breakthroughs that years of traditional therapy hadn’t delivered. Source: Psychology Today
The Results Are Hard to Ignore
- 1 in 3 people with major depressive disorder have or will develop treatment-resistant depression. That’s the exact population psilocybin therapy was developed for.
- Compass Pathways’ COMP360 met its primary endpoint in both Phase 3 trials with a single dose. Source: Psychiatry Times
- A single administration demonstrated a highly statistically significant reduction in depression symptom severity. Source: SEC
- The FDA fast-tracked three psychedelic compounds in April 2026. It’s the clearest regulatory signal yet that approval is a matter of when, not if. Source: Scientific American
What’s Next for Psychedelic Therapy
The timeline is moving faster than most people realize.
Compass Pathways is on track to submit its FDA application for psilocybin later in 2026. The FDA is also fast-tracking several other psilocybin and MDMA-adjacent compounds, and the political environment has shifted significantly in favor of accelerating patient access. Sources: Healtheconomics, Scientific American
Compass has already partnered with Greenbrook TMS and Hackensack Meridian Health (one of New Jersey’s largest healthcare networks) to prepare for potential delivery of psilocybin treatment if and when it’s approved. Source: Stock Titan
Researchers and clinicians are building the infrastructure. The trials have worked. The approvals are coming.
Start With What’s Available Now
Living with treatment-resistant depression or PTSD is exhausting. If you’ve been searching for something that actually works differently, you deserve to know what your options are today. Not just what might be available in a few years.
While not a psychedelic, Spravato® is derived from ketamine, a compound with a decades-long safety record. It’s the only FDA-approved psychedelic-adjacent treatment currently available; it’s covered by insurance, and it’s administered in a certified clinical setting right now in our centers throughout New Jersey. Our team will walk you through everything: what the treatment involves, whether you’re a candidate, and what your insurance covers — before you commit to anything.
While the psychedelic field moves toward what comes next, Spravato® is what’s available today for people who want relief now. Your first step is a free, no-pressure conversation with a specialist who understands what you’ve been through.
Who This Might Be Right For
You may be ready to explore these options if any of this sounds familiar:
- You’ve tried at least two antidepressants without finding lasting relief.
- You’re living with treatment-resistant depression, PTSD, or both.
- You feel like you’ve worked through the standard treatment path without the results you were hoping for.
- You want to understand what’s coming in next-generation mental health care, including what you can access right now.
At Oasis, we start every patient relationship the same way: a free, no-pressure conversation to understand where you are and what you’ve already tried. There’s no commitment in that first step. Just answers.
Book your free consultation at Oasis today.
Frequently Asked Questions
What is psychedelic therapy?
Think of it less like taking a drug and more like a guided inner experience, with trained therapists beside you throughout, in a clinical setting. Researchers study controlled doses of compounds like psilocybin or MDMA to treat mental health conditions like depression and PTSD. The goal is breakthroughs that traditional treatment hasn’t delivered.
Is psilocybin FDA-approved?
Not yet, but it’s close. Compass Pathways has completed two successful Phase 3 trials and plans to submit its FDA application later in 2026. In the meantime, Spravato® (esketamine) is the only FDA-approved treatment of this type currently available.
Is any psychedelic-type treatment covered by insurance?
Yes. Spravato® is covered by insurance for treatment-resistant depression. Psilocybin and MDMA treatments are not yet available outside of clinical trials and aren’t currently covered.
What’s the difference between Spravato® and psilocybin?
Both work on brain pathways that traditional antidepressants don’t target. Spravato® acts on glutamate receptors and is derived from ketamine. Psilocybin acts on serotonin receptors and produces a longer, more immersive experience. Spravato® is FDA-approved and available now. Psilocybin is in late-stage trials with approval on the horizon.
Sources:
Beckley Foundation, Psychedelic Research Timeline (Beckley Foundation)
Compass Pathways, COMP005 Phase 3 Results, June 2025 (Compass Pathways IR)
Compass Pathways, COMP006 Phase 3 Results, February 2026 (Compass Pathways IR)
HealthEconomics.com, Compass Pathways Phase 3 Results & FDA Timeline (HealthEconomics.com)
Scientific American, FDA Fast-Tracks Psychedelic Review, April 2026 (Scientific American)
Stat News, FDA MDMA Response Letter, October 2025 (Stat News)
Live Science, MDMA-Assisted Therapy PTSD Trial Results (Live Science)
American Psychological Association, The Emergence of Psychedelics as Medicine (APA)
Psychology Today, Psilocybin for Depression (Psychology Today)
